1. 宫颈癌患者组织和血清外泌体 IncRNA DLX6 - AS1 的表达.
- Author
-
林丽慧, 闫志强, 任青, and 曾思衡
- Abstract
Objective To investigate the expression levels and clinical significance of long non DLX6-AS1 (IncRNA DLX6-ASI) in tissues and serum exosomes of cervical cancer patients. Methods coding RNA Eighty - two cervical cancer patients admitted between April 2022 and April 2023 at the Department of Gynecology, Hainan West Central Hospital were included as the study group, and 82 women with uterine fibroids were selected as the control group. Cervical cancer tissues and serum exosomes were collected postoperatively from the patients. The expression levels of IncRNA DLX6-AS1 in tissue samples and serum exosomes were quantified using real-time quantitative PCR (qRT-PCR). The clinical diagnostic value of IncRNA DLX6-AS1 for cervical cancer was evaluated using receiver operating characteristic (ROC) curve analysis. Results The relative expression levels of IncRNA DLX6 AS1 in both cervical cancer tissues and serum exosomes were significantly higher in the study group compared to the control group (P<0.05). Statistical differences in IncRNA DLX6 - AS1 expression were observed in cervical cancer tissues and serum exosomes among patients at different FIGO stages and with lymph node metastasis or not (P<0.05). The area under the ROC curve (AUC) for diagnosing cervical cancer using IncRNA DLX6-AS1 alone in tissue, alone in serum exosomes, and in combination were 0. 740, 0.692, and 0.781, respectively. Conclusion Elevated expression levels of IncRNA DLX6 AS1 in both tissues and serum exosomes are associated with cervical cancer and its severity. IncRNA DLX6ASI may serve as a potential biomarker for the diagnosis and prognosis of cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF